Population studies estimate that patients who have episodic migraine transition to chronic
migraine at a rate of about 2.5% per year.
CM is a devastating disorder associated to severe disability. Patients with CM frequently
overuse symptomatic medications in the attempt to control their disease, which adds up to the
high costs associated to the disorder In this frame, it seems of the outmost importance to
strive at preventing the transition from EM to CM.
At the moment Onabotulinum toxin A (BoNT-A) represents the only drug specifically approved
for CM prophylaxis.
The aim of the present study was to evaluate the efficacy of BoNT-A in reducing the number of
migraine days in a population of migraineurs with a high frequency of migraine attacks over a
12-month period.
Phase:
Phase 2
Details
Lead Sponsor:
IRCCS National Neurological Institute "C. Mondino" Foundation